Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
15 March 2021Website:
http://peak-bio.comNext earnings report:
N/ALast dividends:
N/ANext dividends:
N/APrice
regular market | Thu, 27 Jun 2024 13:30:00 GMTDividend
Analysts recommendations
Institutional Ownership
What type of business is Peak Bio?
Peak Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics addressing unmet needs in the areas of oncology and inflammation. The company's proprietary toxin, PH-1 or Thailanstatin, a spliceosome modulator is being used to generate its first pipeline of novel ADC product candidates to address unmet needs in cancer patients. Its lead product candidate, PHP-303, is a small molecule awaiting Phase II dose clinical study in the orphan disease Alpha1 anti-trypsin deficiency (AATD). The company is based in Palo Alto, California.
What sector is Peak Bio in?
Peak Bio is in the Healthcare sector
What industry is Peak Bio in?
Peak Bio is in the Biotechnology industry
What country is Peak Bio from?
Peak Bio is headquartered in United States
When did Peak Bio go public?
Peak Bio initial public offering (IPO) was on 15 March 2021
What is Peak Bio website?
https://peak-bio.com
Is Peak Bio in the S&P 500?
No, Peak Bio is not included in the S&P 500 index
Is Peak Bio in the NASDAQ 100?
No, Peak Bio is not included in the NASDAQ 100 index
Is Peak Bio in the Dow Jones?
No, Peak Bio is not included in the Dow Jones index
When does Peak Bio report earnings?
Next earnings report date is not announced yet